Concepts of ‘Personalization’ in Personalized Medicine: Implications for Economic Evaluation

PharmacoEconomics

Volumn 33, Issue 1, 2015, Pages 49-59

  Rogowski, Wolf ^a,b   Payne, Katherine ^c   Schnell Inderst, Petra ^d,e   Manca, Andrea ^h   Rochau, Ursula ^d,e   Jahn, Beate ^d,e   Alagoz, Oguzhan ^j   Leidl, Reiner ^a,i   Siebert, Uwe ^d,e,f,g  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^e Oncotyrol Center for Personalized Cancer Medicine   (Austria)

^f HARVARD MEDICAL SCHOOL   (United States)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^h UNIVERSITY OF YORK   (United Kingdom)

ⁱ UNIVERSITY OF MUNICH   (Germany)

^j UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; CONCEPTUAL FRAMEWORK; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; ECONOMIC EVALUATION; EVIDENCE BASED PRACTICE; HEALTH PROMOTION; HUMAN; MEDICAL EXPERT; MEDICAL LITERATURE; PATIENT COMPLIANCE; PATIENT DECISION MAKING; PATIENT PREFERENCE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RISK MANAGEMENT; SYSTEMATIC REVIEW (TOPIC); THEMATIC ANALYSIS; TREATMENT REFUSAL; UNCERTAINTY; WORKSHOP; COST BENEFIT ANALYSIS; DECISION MAKING; ECONOMICS; HEALTH CARE DELIVERY; PROCEDURES;

COST-BENEFIT ANALYSIS; DECISION MAKING; DELIVERY OF HEALTH CARE; HUMANS; PRECISION MEDICINE;

EID: 84922006725     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-014-0211-5     Document Type: Article

References (62)

1. Schleidgen S, Klingler C, Bertram T, Rogowski WH, Marckmann G. What is personalized medicine: sharpening a vague term based on a systematic literature review. BMC Med Ethics. 2013;14:55.
2. Faulkner E, Annemans L, Garrison L, Helfand M, Holtorf AP, Hornberger J, et al. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group. Value Health. 2012;15(8):1162–71.
3. Berger AC, Olson S. The economics of genomic medicine: workshop summary. Washington, DC: The National Academies; 2013.
4. Rogowski WH, Grosse SD, Khoury MJ. Challenges of translating genetic tests into clinical and public health practice. Nat Rev Genet. 2009;10(7):489–95.
5. Annemans L, Redekop K, Payne K. Current methodological issues in the economic assessment of personalized medicine. Value Health. 2013;16(6 Suppl):S20–6.
6. Bloss G, Haaga JG. Economics of personalized health care and prevention: introduction. Forum Health Econ Policy. 2013;16(2):35–45.
7. Sorich MJ, Wiese MD, O’Shea RL, Pekarsky B. Review of the cost effectiveness of pharmacogenetic-guided treatment of hypercholesterolaemia. Pharmacoeconomics. 2013;31(5):377–91.
8. Vegter S, Boersma C, Rozenbaum M, Wilffert B, Navis G, Postma MJ. Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines. Pharmacoeconomics. 2008;26(7):569–87.
9. Payne K, Newman WG, Gurwitz D, Ibarreta D, Phillips KA. TPMT testing in azathioprine: a ‘cost-effective use of healthcare resources’? Personal Med. 2009;6(1):103–13.
10. Wong WB, Carlson JJ, Thariani R, Veenstra DL. Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics. 2010;28(11):1001–13.
11. Phillips KA, Ann Sakowski J, Trosman J, Douglas MP, Liang SY, Neumann P. The economic value of personalized medicine tests: what we know and what we need to know. Genet Med. 2014;16(3):251–7.
12. Basu A. Economics of individualization in comparative effectiveness research and a basis for a patient-centered health care. J Health Econ. 2011;30(3):549–59.
13. Basu A, Meltzer D. Value of information on preference heterogeneity and individualized care. Med Decis Making. 2007;27(2):112–27.
14. Payne K, Thompson AJ. Economics of pharmacogenomics: rethinking beyond QALYs? Curr Pharmacogenomics Personal Med. In press.
15. Jones J, Hunter D. Consensus methods for medical and health services research. BMJ. 1995;311(7001):376–80.
16. Ding A, Eisenberg JD, Pandharipande PV. The economic burden of incidentally detected findings. Radiol Clin North Am. 2011;49(2):257–65.
17. Carlson JJ, Henrikson NB, Veenstra DL, Ramsey SD. Economic analyses of human genetics services: a systematic review. Genet Med. 2005;7(8):519–23.
18. Rogowski W. Genetic screening by DNA technology: a systematic review of health economic evidence. Int J Technol Assess Health Care. 2006;22(3):327–37.
19. Djalalov S, Musa Z, Mendelson M, Siminovitch K, Hoch J. A review of economic evaluations of genetic testing services and interventions (2004–2009). Genet Med. 2011;13(2):89–94.
20. Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–3. Value Health. 2012;15(6):812–20.
21. Karnon J, Stahl J, Brennan A, Caro JJ, Mar J, Moller J. Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–4. Value Health. 2012;15(6):821–7.
22. Mvundura M, Grosse SD, Hampel H, Palomaki GE. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med. 2010;15(12):93–104.
23. Basu A, Jena AB, Goldman DP, Philipson TJ, Dubois R. Heterogeneity in action: the role of passive personalization in comparative effectiveness research. Health Econ. Epub 9 Oct 2013. doi:10.1002/hec.2996
24. Espinoza M, Manca A, Claxton K, Sculpher M. The value of heterogeneity for cost-effectiveness subgroup analysis: conceptual framework and application. Med Decis Making. Epub 18 Jun 2014.
25. Paget MA, Chuang-Stein C, Fletcher C, Reid C. Subgroup analyses of clinical effectiveness to support health technology assessments. Pharm Stat. 2011;10:532–8.
26. Laking G, Lord J, Fischer A. The economics of diagnosis. Health Econ. 2006;15(10):1109–20.
27. Grigore B, Peters J, Hyde C, Stein K. Methods to elicit probability distributions from experts: a systematic review of reported practice in health technology assessment. Pharmacoeconomics. 2013;31(11):991–1003.
28. Johnson ML, Crown W, Martin BC, Dormuth CR, Siebert U. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report–Part III. Value Health. 2009;12(8):1062–73.
29. Rogowski W, Burch J, Palmer S, Craigs C, Golder S, Woolacott N. The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis. Health Technol Assess. 2009;13(31):1–102.
30. Siebert U, Rochau U, Claxton K. When is enough evidence enough? Using systematic decision analysis and value-of-information analysis to determine the need for further evidence. Z Evid Fortbild Qual Gesundhwes. 2013;107(9–10):575–84.
31. Rogowski WH, Grosse SD, Meyer E, John J, Palmer S. Using value of information analysis in decision making about applied research. The case of genetic screening for hemochromatosis in Germany. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012;55(5):700–9.
32. Philips Z, Claxton K, Palmer S. The half-life of truth: what are appropriate time horizons for research decisions? Med Decis Mak. 2008;28(3):287–99.
33. Hatz MH, Schremser K, Rogowski WH. Is individualized medicine more cost-effective? A systematic review. Pharmacoeconomics. 2014;32(5):443–55.
34. Koerber F, Waidelich R, Stollenwerk B, Rogowski W. The cost-utility of open prostatectomy compared with active surveillance in early localised prostate cancer. BMC Health Serv Res. 2014;14(1):163.
35. Elliott RA, Shinogle JA, Peele P, Bhosle M, Hughes DA. Understanding medication compliance and persistence from an economics perspective. Value Health. 2008;11(4):600–10.
36. Issa AM. Personalized medicine and the practice of medicine in the 21st century. Mcgill J Med. 2007;10(1):53–7.
37. Robins J, Hernan M, Siebert U. Effects of multiple interventions. In: Ezzati M, Lopez AD, Rodgers A, Murray CJL, editors. Comparative quantification of health risks: global and regional burden of disease attributable to selected major risk factors. Geneva: World Health Organization; 2004. p. 2191–230.
38. Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health–a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14(4):403–13.
39. Reed Johnson F, Lancsar E, Marshall D, Kilambi V, Muhlbacher A, Regier DA, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health. 2013;16(1):3–13.
40. Johnson FR, Hauber AB, Ozdemir S, Lynd L. Quantifying women’s stated benefit-risk trade-off preferences for IBS treatment outcomes. Value Health. 2010;13(4):418–23.
41. Harrison M, Rigby D, Vass C, Flynn T, Louviere J, Payne K. Risk as an attribute in discrete choice experiments: a systematic review of the literature. Patient. 2014;7(2):151-170.
42. Ersig AL, Hadley DW, Koehly LM. Colon cancer screening practices and disclosure after receipt of positive or inconclusive genetic test results for hereditary nonpolyposis colorectal cancer. Cancer. 2009;115(18):4071–9.
43. Rice T. The behavioral economics of health and health care. Annu Rev Public Health. 2013;34:431–47.
44. Hole AR. Modelling heterogeneity in patients’ preferences for the attributes of a general practitioner appointment. J Health Econ. 2008;27(4):1078–94.
45. Fiebig DG, Keane MP, Louviere J, Wasi N. The generalized multinomial logit model: accounting for scale and coefficient heterogeneity. Mark Sci. 2010;29(3):393–421.
46. Tremmel JC. A theory of intergenerational justice. Düsseldorf: Heinrich-Heine Universität; 2009.
47. Gough I. Lists and thresholds: comparing the Doyal-Gough theory of human need with Nussbaum’s capabilities approach. In: Comim F, Nussbaum M, editors. Capabilities, gender, equality: towards fundamental entitlements. New York: Cambridge University Press; 2014.
48. Brouwer WB, Culyer AJ, van Exel NJ, Rutten FF. Welfarism vs. extra-welfarism. J Health Econ. 2008;27(2):325–38.
49. Rogowski W. Current impact of gene technology on healthcare. A map of economic assessments. Health Policy. 2007;5(80):340–57.
50. Rogowski WH, Grosse SD, John J, Kääriäinen H, Kent A, Kristofferson U, et al. Points to consider in assessing and appraising predictive genetic tests. J Community Genet. 2010;1(4):185–94.
51. Grosse SD, Wordsworth S, Payne K. Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis. Genet Med. 2008;10(9):648–54.
52. Neumann PJ, Cohen JT, Hammitt JK, Concannon TW, Auerbach HR, Fang C, et al. Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. Health Econ. 2012;21(3):238–51.
53. Smith RD, Sach TH. Contingent valuation: what needs to be done? Health Econ Policy Law. 2010;5(Pt 1):91–111.
54. Rogowski WH, Hartz SC, John JH. Clearing up the hazy road from bench to bedside: a framework for integrating the fourth hurdle into translational medicine. BMC Health Serv Res. 2008;8(194):1–12.
55. Fischer KE, Rogowski WH, Leidl R, Stollenwerk B. Transparency vs. closed-door policy: do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis. Health Policy. 2013;112(3):187–96.
56. Culyer A. Need: an instrumental view. In: Ashcroft RE, editor. Principles of health care ethics. Edited by Richard E. Ashcroft, et al. 2nd ed. Chichester: Wiley; 2007. p. 231–8.
57. Guindo LA, Wagner M, Baltussen R, Rindress D, van Til J, Kind P, et al. From efficacy to equity: Literature review of decision criteria for resource allocation and healthcare decision making. Cost Eff Resour Alloc. 2012;10(1):9.
58. Payne K, McAllister M, Davies LM. Valuing the economic benefits of complex interventions: when maximising health is not sufficient. Health Econ. 2013;22(3):258-271.
59. McAllister M, Dunn G, Payne K, Davies L, Todd C. Patient empowerment: the need to consider it as a measurable patient-reported outcome for chronic conditions. BMC Health Serv Res. 2012;12:157.
60. Juengst ET, Flatt MA, Settersten Jr RA. Personalized genomic medicine and the rhetoric of empowerment. Hastings Cent Rep. 2012;42(5):34–40.
61. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn’t. BMJ. 1996;312(7023):71–2.
62. Montori VM, Brito JP, Murad MH. The optimal practice of evidence-based medicine: incorporating patient preferences in practice guidelines. JAMA. 2013;310(23):2503–4.